Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Final Results of A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Quizartinib (AC220) Administered Daily to Patients with Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FLT3-ITD Status

Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, James M. Foran, MD, FRCPC, Darejan Ghirdaladze, Mamia Zodelava, Gautam Borthakur, M.D., Guy Gammon, MD, Denise Trone, Robert C Armstrong, Ph.D., Joyce James, Mark J. Levis, MD, PhD

Blood (2012) 120 (21): 1507.

https://doi.org/10.1182/blood.V120.21.1507.1507

Published: 2012

Journal Articles

Racial Disparities in Cell of Origin Among DLBCL Patients.

Christopher R. Flowers, MD, Loretta Nastoupil, MD, Uma Borate, MD, MS, Pareen J Shenoy, MBBS, MPH, Will Donnellan, Nassoma King, PA, Kevin Bumpers, MHA, Mary Jo Lechowicz, MD, Leon Bernal-Mizrachi, M.D., Rajni Sinha, MD, MRCP, Elizabeth Chastain, MD, Kevin E Fisher, M.D., Ph.D., James M. Foran, MD, FRCPC, Vishnu Reddy, MD, David L Jaye, MD

Blood (2012) 120 (21): 2686.

https://doi.org/10.1182/blood.V120.21.2686.2686

Published: 2012

Journal Articles

First-Line Prescribing Preferences of American Hematology-Oncology Physicians for Patients with CLL: Impact of Age, Co-Morbidities, and Tempo of Disease

Mark R. Green, MD, Michael E. Williams, MD, Joanne Willey, RN, Mitchell Scharf, Douglas Neely, Michael G. Heckman, MS, James M. Foran, MD, FRCPC

Blood (2012) 120 (21): 4608.

https://doi.org/10.1182/blood.V120.21.4608.4608

Published: 2012

Journal Articles

Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease

Blood (2012) 120 (21): 677.

https://doi.org/10.1182/blood.V120.21.677.677

Published: 2012

Journal Articles

Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

James M. Foran, MD, FRCPC, Cristine Allmer, BS, Alice H Wang, BA, Carrie A. Thompson, MD, Jennifer L. Kelly, PhD, MPH, Grzegorz S. Nowakowski, MD, Matthew J Maurer, MS, Susan L Slager, PhD, David J. Inwards, MD, Stephen M. Ansell, M.D., Ph.D., Thomas E. Witzig, MD, Brian K Link, MD, Thomas M Habermann, MD, James R Cerhan, MD, PhD

Blood (2012) 120 (21): 684.

https://doi.org/10.1182/blood.V120.21.684.684

Published: 2012

Journal Articles

Combination of Lenalidomide with R-CHOP (R2CHOP) Is Well-Tolerated and Effective As Initial Therapy for Aggressive B-Cell Lymphomas - A Phase II Study

Grzegorz S. Nowakowski, MD, Betsy R. LaPlant, Craig Reeder, MD, James M. Foran, MD, FRCPC, Luis F. Porrata, MD, William R Macon, MD, Patrick B. Johnston, MD, PhD, Candido E. Rivera, MD, Thomas M Habermann, MD, David J. Inwards, MD, Ivana N. Micallef, MD, Garth D Nelson, Stephen M. Ansell, M.D., Ph.D., Thomas E. Witzig, MD

Blood (2012) 120 (21): 689.

https://doi.org/10.1182/blood.V120.21.689.689

Published: 2012

Journal Articles

The Impact of Obesity on the Presentation & Outcome of Adult Acute Myeloid Leukemia (AML) - ECOG Studies E1900 & E3999

James M. Foran, MD, FRCPC, Zhuoxin Sun, PhD, Hugo F. Fernandez, MD, Larry D Cripe, MD, Rhett P Ketterling, MD, Janis Racevskis, PhD, Selina M. Luger, MD, Elisabeth Paietta, PhD, Hillard M. Lazarus, MD, FACP, Mark R. Litzow, MD, Martin S. Tallman, MD

Blood (2011) 118 (21): 2568.

https://doi.org/10.1182/blood.V118.21.2568.2568

Published: 2011

Journal Articles

Treatment of Higher-Risk Myelodysplastic Syndrome (MDS) by American Hematology-Oncology Providers (AHOP's): Changes in 1st-Line Treatment Preferences Over Time in Relation to Cytogenetics & Survival Data From Randomized Studies (2006–2010),

James M. Foran, MD, FRCPC, Michael G. Heckman, MS, Michael E. Williams, MD, Joanne Willey, RN, Mark R. Green, MD

Blood (2011) 118 (21): 3816.

https://doi.org/10.1182/blood.V118.21.3816.3816

Published: 2011

Journal Articles

A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, In Older Patients with MDS Refractory to Hypomethylating Agents

Guillermo Garcia-Manero, MD, Selina Luger, MD, Parmeswaran Venugopal, MD, Lori Maness, MD, Meir Wetzler, MD, Jessica K Altman, MD, David F. Claxton, MD, Stephen Anthony Strickland, JR, MD, James M. Foran, MD, FRCPC, Stuart L Goldberg, MD, Judy Chiao, MD, Hagop M. Kantarjian, MD

Blood (2010) 116 (21): 1857.

https://doi.org/10.1182/blood.V116.21.1857.1857

Published: 2010

Journal Articles

GSK1120212, a MEK1/MEK2 Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity In a Dose Rising Trial In Subjects with AML and Other Hematologic Malignancies

Gautam Borthakur, MD, James M. Foran, MD, FRCPC, Tapan Kadia, MD, Elias Jabbour, MD, Paul Wissel, MD, Donna Cox, PhD, Yanmei Xu, PhD, John Bauman, PhD, Melanie Baccus, RN, Jeanne Connor, RN, OCN, Jorge E. Cortes, MD, Hagop Kantarjian, MD

Blood (2010) 116 (21): 3281.

https://doi.org/10.1182/blood.V116.21.3281.3281

Published: 2010

Journal Articles

Examining the Racial Disparities In Presentation and Treatment for Patients with Diffuse Large B-Cell Lymphoma (DLBCL).

Pareen J Shenoy, MBBS, MPH, Uma Borate, MD, MS, Kevin Bumpers, MHA, Tanyanika Douglas-Holland, MD, Nassoma King, PA, Mary Jo Lechowicz, MD, David L Jaye, MD, Will Donnellan, MD, Angelina The, MD, BS, Vishnu Reddy, MD, James M. Foran, MD, FRCPC, Christopher R Flowers, MD, MS

Blood (2010) 116 (21): 1521.

https://doi.org/10.1182/blood.V116.21.1521.1521

Published: 2010

Journal Articles

Use of Rituximab with CHOP Chemotherapy Appears to Overcome Racial Disparities In Survival In Black Patients with Diffuse Large B Cell Lymphoma When Compared to CHOP Chemotherapy Alone.

Uma Borate, MD, MS, Pareen J Shenoy, MBBS, MPH, Will Donnellan, Kevin Bumpers, MHA, Tanyanika Douglas-Holland, MD, Nassoma King, PA, Mary Jo Lechowicz, MD, Angelina The, MD, BS, David L Jaye, MD, Vishnu Reddy, Christopher R Flowers, MD, MS, James M. Foran, MD, FRCPC

Blood (2010) 116 (21): 1528.

https://doi.org/10.1182/blood.V116.21.1528.1528

Published: 2010

NARROW

Final Results of A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Quizartinib (AC220) Administered Daily to Patients with Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FLT3-ITD Status

Racial Disparities in Cell of Origin Among DLBCL Patients.

First-Line Prescribing Preferences of American Hematology-Oncology Physicians for Patients with CLL: Impact of Age, Co-Morbidities, and Tempo of Disease

Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease

Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

Combination of Lenalidomide with R-CHOP (R2CHOP) Is Well-Tolerated and Effective As Initial Therapy for Aggressive B-Cell Lymphomas - A Phase II Study

The Impact of Obesity on the Presentation & Outcome of Adult Acute Myeloid Leukemia (AML) - ECOG Studies E1900 & E3999

Treatment of Higher-Risk Myelodysplastic Syndrome (MDS) by American Hematology-Oncology Providers (AHOP's): Changes in 1st-Line Treatment Preferences Over Time in Relation to Cytogenetics & Survival Data From Randomized Studies (2006–2010),

A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, In Older Patients with MDS Refractory to Hypomethylating Agents

GSK1120212, a MEK1/MEK2 Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity In a Dose Rising Trial In Subjects with AML and Other Hematologic Malignancies

Examining the Racial Disparities In Presentation and Treatment for Patients with Diffuse Large B-Cell Lymphoma (DLBCL).

Use of Rituximab with CHOP Chemotherapy Appears to Overcome Racial Disparities In Survival In Black Patients with Diffuse Large B Cell Lymphoma When Compared to CHOP Chemotherapy Alone.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only